

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application No.	10/642,807
Filing Date	August 15, 2003
First Named Inventor	Lewis et al.
Art Unit	1623
Examiner Name	Peselev
Attorney Docket No.	892,280-602 (formerly 342312004900)

Sheet	1	of	5
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Document No. Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
✓	1.	2,851,463	09/09/1958	Hinman et al.	
✓	2.	2,928,844	03/15/1960	De Boer et al.	
✓	3.	3,255,174	06/07/1966	Bannister et al.	
✓	4.	3,268,556	08/23/1966	Hoeksema	
✓	5.	3,282,917	11/01/1966	Magerlein	
✓	6.	3,361,739	01/02/1968	Argoudelis et al.	
✓	7.	3,364,197	01/16/1968	Hoeksema	
✓	8.	3,380,992	04/30/1968	Argoudelis et al.	
✓	9.	3,435,025	05/25/1969	Birkenmeyer	
✓	10.	3,539,689	11/10/1970	Birkenmeyer et al.	
✓	11.	3,549,615	12/22/1970	Birkenmeyer	
✓	12.	3,555,007	01/12/1971	Magerlein	
✓	13.	3,702,322	11/07/1972	Bannister	
✓	14.	3,817,979	06/18/1974	Argoudelis et al.	
✓	15.	3,856,943	12/24/1974	Birkenmeyer	
✓	16.	3,892,729	07/01/1975	Birkenmeyer	
✓	17.	3,892,730	07/01/1975	Birkenmeyer	
✓	18.	4,293,547	10/06/1981	Lewis et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
✓	19.	EP 0161 794	11/21/1985	The Upjohn Company		
✓	20.	GB 1 298 295	11/29/1972	The Upjohn Company		
✓	21.	GB 1 347 598	02/27/1974	The Upjohn Company		
✓	22.	WO 89/04672	06/01/1989	The Upjohn Company		

NB1:662843. 2Examiner
Signature

C. Peselev

Date
Considered

10/7/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB-08a (08 03)

American LegalNet Inc.
www.USCourtForms.com

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
				Application No.	10/642,807
				Filing Date	August 15, 2003
				First Named Inventor	Lewis
				Art Unit	1623
Examiner Name	Peselev				
Sheet	2	of	5	Attorney Docket No.	892,280-602 (formerly 342312004900)

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ Kind Code (if known)			
✓	23.	WO	2004/016632	02/26/2004	Vicuron Pharmaceuticals Inc.	
✓	24.	WO	2005/012320	02/10/2005	Vicuron Pharmaceuticals Inc.	
✓	25.	WO	2005/007665	01/27/2005	Vicuron Pharmaceuticals Inc.	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published	T ²
✓	26.	Alexander, J. et al. (1988) "(Acyloxy)alkyl Carbamates as Novel Bioreversible Prodrugs for Amines: Increased Permeation through Biological Membranes," JOURNAL OF MEDICINAL CHEMISTRY 31(2): 318-22.	
✓	27.	Alexander, J. et al. (1996) "Investigation of (Oxodioxolonyl)methyl Carbanates as Nonchiral Bioreversible Prodrug Moieties for Chiral Amines," JOURNAL OF MEDICINAL CHEMISTRY 39(2): 480-86.	
✓	28.	Corrected version of International Search Report mailed on July 26, 2004, for International Application PCT/US03/25820 filed on August 15, 2003	
✓	29.	International Search Report mailed on May 6, 2005, for PCT Patent Application PCT/US2004/019497 filed on June 17, 2004, 7 pages	
✓	30.	International Search Report mailed on August 8, 2005, for PCT Patent Application PCT/US2004/019689 filed on June 17, 2004, 21 pages	
✓	31.	Baldwin, J.E. et al. (1990) "Stereospecific Synthesis of Dealanylalohopein," TETRAHEDRON 46 (13/14): 4733-48.	

NB1:662843. 2Examiner Signature	<i>E. Keller</i>	Date Considered	10/1/05
---------------------------------	------------------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB-08a (08 03)
American LegalNet Inc. www.USCourtForms.com

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application No.	10/642,807
				Filing Date	August 15, 2003
				First Named Inventor	Lewis
				Art Unit	1623
				Examiner Name	Peselev
Sheet	3	of	5	Attorney Docket No.	892,280-602 (formerly 342312004900)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published	T ²
✓	32.	Bannister, B. et al. (1980) "The S-Alkylation of Sulphides by an Activated Carbohydrate Epimine Under Acidic Catalysis: the Formation of α-Acetamido-sulphides. Part 4. Reactions with Dithioacetals and Monothioacetals" JOURNAL OF THE CHEMICAL SOCIETY, PERKINS TRANSACTIONS 1 2:540-552	
✓	33.	Bannister, B. et al. (1987) "The S-Alkylation of Sulphides by an Activated Carbohydrate Epimine Under Acidic Catalysis: the Formation of α-Acetamido-sulphides. Part 5. The Introduction of Functionality into the Sulphide Substituent" J. CHEM. RES. 4:701-94	
✓	34.	Bannister, B. et al. (1989) "The S-Alkylation of Sulphides by an Activated Carbohydrate Epimine Under Acidic Catalysis: the Formation of α-Acetamido-sulphides. Part 5. The Introduction of Functionality into the Sulphide Substituent" JOURNAL OF CHEMICAL RESEARCH 4:90-91	
✓	35.	Bousquet, Y. et al. (1997) "Preparation of Enantiopure 4-Oxygenated Pipeolic Acid Derivatives," TETRAHEDRON 53(46): 15671-15680.	
✓	36.	Bundgaard, H. et al. (1980) "Prodrugs as Drug Delivery Systems IV: N-Mannich bases as Potential Novel Prodrugs for Amides, Ureide, Amines, and Other NH-Acidic Compounds," JOURNAL OF PHARMACEUTICAL SCIENCES 69(1): 44-46.	
✓	37.	Deiters, A. et al. (2004) "Synthesis of Oxygen- and Nitrogen-Containing Heterocycles by Ring-Closing Metathesis" CHEM. REV. 104: 2199-2238.	
✓	38.	Del Valle, J.R. et al. (2003) "Asymmetric Hydrogenations for the Synthesis of Boc-Protected 4-Alkylprolinols and Prolines," JOURNAL OF ORGANIC CHEMISTRY 68(10): 3923-31.	
✓	39.	Dondoni, A. et al. (1997) "Stereoselective Addition of 2-Furyllithium and 2-Thiazolylithium to Sugar Nitrones. Synthesis of Carbon-Linked Glycoglycines." JOURNAL OF ORGANIC CHEMISTRY 62(16): 5484-96.	
✓	40.	Dondini, A. (1994) "Synthesis of N-Benzyl Nitrones" SYNTHETIC COMMUNICATIONS 24(18):2537-50.	

NB1:662843. 2 Examiner Signature <i>E. Kuhl</i>	Date Considered	10/21/06
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p>		
		PTO/SB-08a (08 03) American LegalNet Inc. www.USCourtForms.com

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known		
				Application No.	10/642,807	
				Filing Date	August 15, 2003	
				First Named Inventor	Lewis	
				Art Unit	1623	
				Examiner Name	Peselev	
Sheet	4	of	5	Attorney Docket No.		892,280-602 (formerly 342312004900)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published	T ²
✓	41.	Flaherty, P. et al. (1996) "Synthesis and Selective Monoamine Oxidase B-Inhibiting Properties of 1-Methyl-2,3,6-Tetrahydropyrid-4-yl Carbamate Derivatives: Potential Prodrugs of (R)- and (S)-Nordeprenyl," JOURNAL OF MEDICINAL CHEMISTRY 39(24): 4756-61.	
✓	42.	Fukuyama, T. et al. (1995) "2- and 4-Nitrobenzenesulfonamides: Exceptionally Versatile Means for Preparation of Secondary Amines and Protection of Amines." TETRAHEDRON LETTERS 36(36): 6373-74.	
✓	43.	Griffith, W.P. et al. (1990) "TPAP: Tetra-n-propylammonium Perruthenate, A Mild and Convenient Oxidant for Alcohols." ALDRICHIMICA ACTA 23(1): 13-19.	
✓	44.	Ibatullin, F.M. et al. (2002) "Reaction of 1,2-trans-glycosyl acetates with phosphorus pentachloride: new efficient approach to 1,2-trans-glycosyl chlorides" TETRAHEDRON LETTERS 43: 9577-9580.	
✓	45.	Jensen, N.P. et al. (1980) "Use of Acetylacetone to Prepare a Prodrug of Cycloserine," JOURNAL OF MEDICINAL CHEMISTRY 23(1): 6-8.	
✓	46.	Magerlein, B.J. et al. (1969) "Lincomycin. VIII. 4'-Alkyl-1'-demethyl-4'-depropylclindamycins, Potent Antibacterial and Antimalarial Agents" JOURNAL OF MEDICINAL CHEMISTRY 12: 780-84.	
✓	47.	Magerlein, B.J. (1967) "Lincomycin. VII. 4'-depropyl-4'-ethoxylincomycins" JOURNAL OF MEDICINAL CHEMISTRY 10(6): 1161-63.	
✓	48.	Misieck, M. et al. (1973) "Microbiological Properties of a New Cephalosporin, BL-S 339: 7-(Phenylacetimidoyl-aminoacetamido)-3-(2-Methyl-1,3,4-Thiadiazol-5-Ylthiomethyl)Ceph-3-em-4-Carboxylic Acid" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 3(1):40-48.	
✓	49.	Myers, A.G. et al. (1999) "Greatly Simplified Procedures for the Synthesis of α-Amino Acids by the Direct Alkylation of Pseudoephedrine Glycinamide Hydrate" J. ORG. CHEM. 64: 3322-27.	
✓	50.	Osuch, C. et al. (1956) "The Use of Organolithium Compounds to effect the Alkylation of 2- and 4-Picoline" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 78:1723-25.	

NB1:662843. 2Examiner
Signature

G. Peselev

Date
Considered

10/7/08

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB-08a (08 03)

American LegalNet Inc.
www.USCourtForms.com

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application No.	10/642,807
				Filing Date	August 15, 2003
				First Named Inventor	Lewis
				Art Unit	1623
				Examiner Name	Peselev
Sheet	5	of	5	Attorney Docket No.	892,280-602 (formerly 342312004900)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published	T ²	
SR	51.	Sakamoto, F. et al. (1984) "Studies on Prodrugs. II. Preparation and Characterization of (5-Substituted 2-Oxo-1,3-Dioxolen-4-yl)methyl Esters of Ampicillin" CHEM. PHARM. BULL. 36(6): 2241-48.		
SR	52.	Shek, E. et al. (1976) "Improved Delivery Through Biological Membranes. 2. Distribution, Excretion, and Metabolism of N-Methyl-1,6-dihydropyridine-2-Carbaldoxime Hydrochloride, A Pro-drug of N-Methylpyridinium-2-Carbaldoxime Chloride" JOURNAL OF MEDICINAL CHEMISTRY 19(1):108-12.		
SR	53.	Spížek, J. et al. (2004) "Lincomycin, Cultivation of Producing Strains and Biosynthesis" APPL. MICROBIOL. BIOTECHNOL. 63:510-19.		
SR	54.	Sztaricskai, F. et al. (1996) "Semisynthetic Modification of Antibiotic Lincomycin" J. ANTIBIOTICS 49(9): 941-43.		
SR	55.	Sztaricskai, F. et al. (1997) "Chemical Synthesis and Structural Study of Lincomycin Sulfoxides and a Sulfone" J. ANTIBIOTICS 50(10): 866-73.		
SR	56.	Sztaricskai, F. et al. (1999) "Structural Modification of the Lincomycin Antibiotic" J. ANTIBIOTICS 52(11): 1050-55.		
SR	57.	Watanabe, T. et al. (1982) "Synthesis of α -Amino-cycloheptatriene-1-acetic Acids and Their 7-Acylaminocephalosporin Derivatives" CHEMICAL PHARMACEUTICAL BULLETIN 30(7): 2579-82.		
SR	58.	Weiss, W.J. et al. (1999) "In vivo Activities of Peptidic Prodrugs of Novel Aminomethyl Tetrahydrofuran-1 β -Methylcarbapenems" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 43(3): 460-64.		
SR	59.	Yong, K. et al. (2001) "Studies on the Alkylation of 3-Methyl-3-buten-1-ol Dianion: An Efficient Synthesis of 3-Methylene-1-alkanols Including a San Jose Scale Sex Pheromone" JOURNAL OF ORGANIC CHEMISTRY 66(24): 8248-51.		

NBI:662843. 2Examiner Signature	<i>E. Peselev</i>	Date Considered	10/1/03
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p>			
			PTO/SB-08a (08 03) American LegalNet Inc. www.USCourtForms.com